menu
    • menu
    [{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"131-Iodine conjugated anti-HER2 sdAb 2Rs15d","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen Theragnostics \/ Precirix"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Iopofosine I-131","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Evergreen Theragnostics \/ Cellectar Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Theragnostics \/ Cellectar Biosciences"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Clovis Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"225Ac-FAP-2286","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Evergreen Theragnostics \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Petrichor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"177Lu-EVG-321","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Petrichor","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Petrichor"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Medical University of Innsbruck","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"177Lu-EVG-321","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Medical University of Innsbruck","highestDevelopmentStatusID":"14","companyTruncated":"Evergreen Theragnostics \/ Medical University of Innsbruck"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"68Ga-EVG321","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evergreen Theragnostics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Evergreen Theragnostics

    Menu

    Evergreen Theragnostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68Ga-EVG321

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evergreen Opens CCK2-VIEW Phase II Trial in EU for Lung Cancer

                            Details : 68Ga-EVG321 is being evaluating in the early-stage clinical trials studies for the treatment of patients with small cell lung cancer in the European Union.

                            Brand Name : 68Ga-EVG321

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2024

                            Lead Product(s) : 68Ga-EVG321

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Medical University of Innsbruck

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evergreen Theragnostics Licenses EVG321 from Innsbruck for Radioligand Therapies

                            Details : The collaboration aims to advance the clinical development of EVG-321 (177Lu-EVG-321), which is being evaluated in the early-stage clinical trial studies for the treatment of small cell lung cancer.

                            Brand Name : EVG-321

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : 177Lu-EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Medical University of Innsbruck

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Petrichor

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Evergreen Theragnostics Completes $26M Capital Raise for Radiopharmaceutical Pipeline

                            Details : Evergreen's financing supports clinical trials for its theragnostic pair, 177Lu-EVG-321 and 68Ga-EVG-321, aimed at small cell lung cancer treatment.

                            Brand Name : EVG-321

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : 177Lu-EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Petrichor

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225Ac-FAP-2286

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Clovis Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Acti...

                            Details : Under the terms of the agreement, Evergreen will develop 225Ac-FAP-2286 at its facility in Springeld, N.J. The facility was purpose-built to develop and manufacture a variety of therapeutic radiopharmaceuticals, including those based on alpha-emitting is...

                            Brand Name : 225Ac-FAP-2286

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : 225Ac-FAP-2286

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Clovis Oncology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iopofosine I-131

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, Now Known as ...

                            Details : The agreement with Evergreen provides long term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase 1 and Phase 2 clinical studies.

                            Brand Name : CLR-131

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : Iopofosine I-131

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Evergreen Theragnostics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-Iodine conjugated anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Precirix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Precirix Partners with Evergreen to Expand North American Clinical Trial Supply

                            Details : Under the terms of the deal, Evergreen will provide US-based manufacturing for Precirix’s lead product candidate, CAM-H2. CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer.

                            Brand Name : CAM-H2

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : 131-Iodine conjugated anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Precirix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth